A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology

ESCMID Study Group for Anaerobic Infections (ESGAI)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Knowledge about the antimicrobial susceptibility patterns of different Prevotella species is limited. The aim of this study was to determine the current antimicrobial susceptibility of clinical isolates of Prevotella species from different parts of Europe, Kuwait and Turkey. Activity of 12 antimicrobials against 508 Prevotella isolates, representing 19 species, were tested according to Etest methodology. EUCAST, CLSI and FDA guidelines were used for susceptibility interpretations. All Prevotella species were susceptible to piperacillin/tazobactam, imipenem, meropenem, tigecycline and metronidazole. Ampicillin/sulbactam and cefoxitin also showed good activity. Ampicillin, clindamycin, tetracycline and moxifloxacin were less active; 51.2%, 33.7%, 36.8% and 18.3% of isolates were non-susceptible, respectively. A total of 49 (9.6%) isolates were resistant to three or more antimicrobials. Prevotella bivia was the most prevalent species (n = 118) and accounted for most of the multidrug-resistant isolates. In conclusion, the level of non-susceptibility to antimicrobials, which may be used for treatment of infections involving Prevotella species, are a cause of concern. This data emphasizes the need for species level identification of clinical Prevotella isolates and periodic monitoring of their susceptibility to guide empirical treatment.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalAnaerobe
Volume52
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Disk Diffusion Antimicrobial Tests
Prevotella
meropenem
Kuwait
Cefoxitin
Clindamycin
Imipenem
Metronidazole
Ampicillin
Turkey
Surveys and Questionnaires
Tetracycline
Guidelines

Keywords

  • Antimicrobial susceptibility
  • Etest
  • Multicenter study
  • Multidrug-resistance
  • Prevotella
  • Surveillance

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases

Cite this

A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology. / ESCMID Study Group for Anaerobic Infections (ESGAI).

In: Anaerobe, Vol. 52, 01.08.2018, p. 9-15.

Research output: Contribution to journalArticle

ESCMID Study Group for Anaerobic Infections (ESGAI). / A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology. In: Anaerobe. 2018 ; Vol. 52. pp. 9-15.
@article{ceba85c645f54ccc8c468e049a95111c,
title = "A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology",
abstract = "Knowledge about the antimicrobial susceptibility patterns of different Prevotella species is limited. The aim of this study was to determine the current antimicrobial susceptibility of clinical isolates of Prevotella species from different parts of Europe, Kuwait and Turkey. Activity of 12 antimicrobials against 508 Prevotella isolates, representing 19 species, were tested according to Etest methodology. EUCAST, CLSI and FDA guidelines were used for susceptibility interpretations. All Prevotella species were susceptible to piperacillin/tazobactam, imipenem, meropenem, tigecycline and metronidazole. Ampicillin/sulbactam and cefoxitin also showed good activity. Ampicillin, clindamycin, tetracycline and moxifloxacin were less active; 51.2{\%}, 33.7{\%}, 36.8{\%} and 18.3{\%} of isolates were non-susceptible, respectively. A total of 49 (9.6{\%}) isolates were resistant to three or more antimicrobials. Prevotella bivia was the most prevalent species (n = 118) and accounted for most of the multidrug-resistant isolates. In conclusion, the level of non-susceptibility to antimicrobials, which may be used for treatment of infections involving Prevotella species, are a cause of concern. This data emphasizes the need for species level identification of clinical Prevotella isolates and periodic monitoring of their susceptibility to guide empirical treatment.",
keywords = "Antimicrobial susceptibility, Etest, Multicenter study, Multidrug-resistance, Prevotella, Surveillance",
author = "{ESCMID Study Group for Anaerobic Infections (ESGAI)} and {Ulger Toprak}, Nurver and Veloo, {Alida C.M.} and E. Urb{\'a}n and Ingrid Wybo and Justesen, {Ulrik S.} and Helene Jean-Pierre and Trefor Morris and Oncu Akgul and Guven Kulekci and Guner Soyletir and E. Nagy",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.anaerobe.2018.05.005",
language = "English",
volume = "52",
pages = "9--15",
journal = "Anaerobe",
issn = "1075-9964",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A multicenter survey of antimicrobial susceptibility of Prevotella species as determined by Etest methodology

AU - ESCMID Study Group for Anaerobic Infections (ESGAI)

AU - Ulger Toprak, Nurver

AU - Veloo, Alida C.M.

AU - Urbán, E.

AU - Wybo, Ingrid

AU - Justesen, Ulrik S.

AU - Jean-Pierre, Helene

AU - Morris, Trefor

AU - Akgul, Oncu

AU - Kulekci, Guven

AU - Soyletir, Guner

AU - Nagy, E.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Knowledge about the antimicrobial susceptibility patterns of different Prevotella species is limited. The aim of this study was to determine the current antimicrobial susceptibility of clinical isolates of Prevotella species from different parts of Europe, Kuwait and Turkey. Activity of 12 antimicrobials against 508 Prevotella isolates, representing 19 species, were tested according to Etest methodology. EUCAST, CLSI and FDA guidelines were used for susceptibility interpretations. All Prevotella species were susceptible to piperacillin/tazobactam, imipenem, meropenem, tigecycline and metronidazole. Ampicillin/sulbactam and cefoxitin also showed good activity. Ampicillin, clindamycin, tetracycline and moxifloxacin were less active; 51.2%, 33.7%, 36.8% and 18.3% of isolates were non-susceptible, respectively. A total of 49 (9.6%) isolates were resistant to three or more antimicrobials. Prevotella bivia was the most prevalent species (n = 118) and accounted for most of the multidrug-resistant isolates. In conclusion, the level of non-susceptibility to antimicrobials, which may be used for treatment of infections involving Prevotella species, are a cause of concern. This data emphasizes the need for species level identification of clinical Prevotella isolates and periodic monitoring of their susceptibility to guide empirical treatment.

AB - Knowledge about the antimicrobial susceptibility patterns of different Prevotella species is limited. The aim of this study was to determine the current antimicrobial susceptibility of clinical isolates of Prevotella species from different parts of Europe, Kuwait and Turkey. Activity of 12 antimicrobials against 508 Prevotella isolates, representing 19 species, were tested according to Etest methodology. EUCAST, CLSI and FDA guidelines were used for susceptibility interpretations. All Prevotella species were susceptible to piperacillin/tazobactam, imipenem, meropenem, tigecycline and metronidazole. Ampicillin/sulbactam and cefoxitin also showed good activity. Ampicillin, clindamycin, tetracycline and moxifloxacin were less active; 51.2%, 33.7%, 36.8% and 18.3% of isolates were non-susceptible, respectively. A total of 49 (9.6%) isolates were resistant to three or more antimicrobials. Prevotella bivia was the most prevalent species (n = 118) and accounted for most of the multidrug-resistant isolates. In conclusion, the level of non-susceptibility to antimicrobials, which may be used for treatment of infections involving Prevotella species, are a cause of concern. This data emphasizes the need for species level identification of clinical Prevotella isolates and periodic monitoring of their susceptibility to guide empirical treatment.

KW - Antimicrobial susceptibility

KW - Etest

KW - Multicenter study

KW - Multidrug-resistance

KW - Prevotella

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=85049327163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049327163&partnerID=8YFLogxK

U2 - 10.1016/j.anaerobe.2018.05.005

DO - 10.1016/j.anaerobe.2018.05.005

M3 - Article

VL - 52

SP - 9

EP - 15

JO - Anaerobe

JF - Anaerobe

SN - 1075-9964

ER -